The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / New SLE Drug May Allow Patients to Reduce Steroid Use

New SLE Drug May Allow Patients to Reduce Steroid Use

December 16, 2015 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270Anifrolumab for Moderate to Severe SLE
The efficacy and safety of anifrolumab (ANIFR), an anti-interferon receptor monoclonal antibody, was assessed in 305 adults with sero-positive moderate to severe systemic lupus erythematosus (SLE), despite standard-of-care medication. This study was a randomized, double-blind, placebo-controlled Phase 2 study.1

You Might Also Like
  • Anifrolumab Promising for SLE
  • AstraZeneca Lupus Drug Fails to Meet Main Goal in Study
  • OA Knee Pain Treatment Enters Clinical Trials, Ixekizumab Receives FDA Approval & Belimumab Promising for SLE Patients
Also By This Author
  • 2 Pediatric Indications Sought for Golimumab

Patients received either 300 mg or 1,000 mg ANIFR intravenously or placebo every four weeks for 48 weeks. The primary endpoint was a composite of Systemic Lupus Erythematosus Responder Index [SRI4] response at Day 169 with sustained reduction in oral steroid use (less than 10 mg daily and less than the Day 1 dose, maintained between Days 85 and 169).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

At Day 169, 34% of 300 mg ANIFR-treated patients met the primary endpoint, as well as 29% of 1,000 mg ANIFR-treated patients, compared with 18% of placebo-treated patients. At Day 365, the secondary SRI endpoint was met by 52% of 300 mg-treated patients (P<0.001 vs. placebo), 39% of 1,000 mg-treated patients and 26% of placebo-treated patients. At Day 365, oral steroids were reduced to ≤7.5 mg per day in 27% of placebo-treated patients, 56% of 300 mg-treated patients and 32% of 1,000 mg-treated patients.

Multiple global and organ-specific benefits were associated with ANIFR use, including a greater than 50% reduction in 28-joint count evaluation compared with placebo. Serious adverse events were reported in 19% of placebo-treated patients and 17% of pooled ANIFR-treated patients. In the ANIFR-treated patients, a higher frequency of influenza and Herpes Zoster was reported.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In Europe, Secukinumab Approved for AS & PsA
Secukinumab (Cosentyx), an IL-17 inhibitor already approved in the U.S. to treat moderate to severe plaque psoriasis, has recently been approved in Europe to treat adults with ankylosing spondylitis (AS) who have not responded to conventional therapy and adults with active psoriatic arthritis (PsA) for whom disease-modifying anti-rheumatic drug therapy has not provided an adequate response.2

In clinical trials, a significant reduction in AS or PsA signs and symptoms was seen within Weeks 1–3 after starting treatment. This symptom reduction was sustained over two years. Up to 80% of AS patients who received secukinumab showed no progression of spinal damage, which was measured by X-ray over two years. In PsA patients, 84% showed no joint damage progression.

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Furie R, Merrill J, Werth V, et al. Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe systemic lupus erythematosus (SLE). Arthritis Rheumatol; 2015 ACR/ARHP Annual Meeting Abstract Supplement. 2015 Oct; 67(S10):1–4046.
  2. McKee S. Novartis’ Cosentyx continues to shine with ‘landmark’ approvals. PharmaTimes Digital. 2015 Nov 24.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, DMARDs & Immunosuppressives, Drug Updates, Spondyloarthritis Tagged With: anifrolumab, Ankylosing Spondylitis, Europe, Psoriatic Arthritis, secukinumab, systemic lupus erythematosus (SLE)

You Might Also Like:
  • Anifrolumab Promising for SLE
  • AstraZeneca Lupus Drug Fails to Meet Main Goal in Study
  • OA Knee Pain Treatment Enters Clinical Trials, Ixekizumab Receives FDA Approval & Belimumab Promising for SLE Patients
  • Rheumatology Drug Updates: Hip Fracture Rates After Bisphosphonate Drug Holidays, Plus More on Golimumab, Ustekinumab

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)